1. Home
  2. LEGN vs CIEN Comparison

LEGN vs CIEN Comparison

Compare LEGN & CIEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • CIEN
  • Stock Information
  • Founded
  • LEGN 2014
  • CIEN 1992
  • Country
  • LEGN United States
  • CIEN United States
  • Employees
  • LEGN N/A
  • CIEN N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • CIEN Telecommunications Equipment
  • Sector
  • LEGN Health Care
  • CIEN Utilities
  • Exchange
  • LEGN Nasdaq
  • CIEN Nasdaq
  • Market Cap
  • LEGN 7.0B
  • CIEN 8.4B
  • IPO Year
  • LEGN 2020
  • CIEN 1997
  • Fundamental
  • Price
  • LEGN $27.78
  • CIEN $81.22
  • Analyst Decision
  • LEGN Strong Buy
  • CIEN Buy
  • Analyst Count
  • LEGN 13
  • CIEN 13
  • Target Price
  • LEGN $75.67
  • CIEN $78.62
  • AVG Volume (30 Days)
  • LEGN 1.5M
  • CIEN 1.5M
  • Earning Date
  • LEGN 05-13-2025
  • CIEN 06-05-2025
  • Dividend Yield
  • LEGN N/A
  • CIEN N/A
  • EPS Growth
  • LEGN N/A
  • CIEN N/A
  • EPS
  • LEGN N/A
  • CIEN 0.55
  • Revenue
  • LEGN $728,303,000.00
  • CIEN $4,049,506,000.00
  • Revenue This Year
  • LEGN $65.96
  • CIEN $12.65
  • Revenue Next Year
  • LEGN $52.55
  • CIEN $8.89
  • P/E Ratio
  • LEGN N/A
  • CIEN $147.80
  • Revenue Growth
  • LEGN 112.46
  • CIEN N/A
  • 52 Week Low
  • LEGN $29.27
  • CIEN $44.69
  • 52 Week High
  • LEGN $60.87
  • CIEN $101.44
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 29.61
  • CIEN 74.40
  • Support Level
  • LEGN $30.25
  • CIEN $78.46
  • Resistance Level
  • LEGN $33.30
  • CIEN $81.48
  • Average True Range (ATR)
  • LEGN 1.78
  • CIEN 2.30
  • MACD
  • LEGN -0.57
  • CIEN 1.15
  • Stochastic Oscillator
  • LEGN 5.19
  • CIEN 98.45

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About CIEN Ciena Corporation

Ciena Corp is a network and technology company. It provides network hardware, software, and services that support the transport, switching, aggregation, service delivery, and management of video, data, and voice traffic on communications networks. It serves various industries such as communication services providers, web-scale providers, cable operators, government, and large enterprises world-wide. The business activities function through Networking Platforms which generates maximum revenue; Platform Software and Services; Blue Planet Automation Software, and Global Services segments. Geographically, the company derives a majority of its revenue from the Americas, and the rest from the Asia-Pacific (APAC), and Europe, Middle East, and Africa (EMEA) region.

Share on Social Networks: